Drugs / LIMANTRAFIN
LIMANTRAFIN
also known as
CB-103 · 6-(4-(1,1-dimethylethyl)phenoxy)-3-pyridinamine · Limantrafina · Limantrafine
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05774899 | Jun 2023 → Jun 2027 expected | adenoid cystic carcinoma | Michael J. Dennis, MD | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03422679 | Dec 2017 → Nov 2022 | T-cell acute lymphoblastic leukemia, adenoid cystic carcinoma, breast cancer, colorectal cancer +3 | Cellestia Biotech AG | Terminated | No outcome recorded Stop: Business |
| Phase 22 trials | ||||||
| Phase 2 | NCT05464836 | Apr 2023 → Aug 2024 | T lymphoblastic leukemia/lymphoma, leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT04714619 | May → Sep 2021 | female breast carcinoma | MedSIR | Terminated | No outcome recorded Stop: Business |
Press releases naming this drug 1 release
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LIMANTRAFIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL1420319 ↗ |
| Known as | 6-(4-(1,1-dimethylethyl)phenoxy)-3-pyridinamine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1420319 ↗ |
| Known as | CB-103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03422679 ↗ |
| Known as | Limantrafina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1420319 ↗ |
| Known as | Limantrafine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1420319 ↗ |
| Action | Inhibit | “pan-NOTCH inhibitor” NCT05774899 ↗ |
| Modality | Small molecule | — CHEMBL1420319 ↗ |
| Route | Oral | “CB-103 will be administered orally in treatment cycles of 28-days each.” NCT03422679 ↗ |